Loading...
Market
Story
US FDA Expands GSK's Jemperli Plus Chemo Approval in Endometrial Cancer
Aug 2, 2024, 11:05 AM
The US FDA has expanded the approval of Jemperli (dostarlimab-gxly) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer. This marks the first and only immuno-oncology-based treatment to demonstrate an overall survival benefit for this patient group. This expanded indication, developed by GSK, is expected to significantly impact treatment protocols and patient outcomes in the field of gynecologic oncology.
View original story
Similar markets
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Hold Lifted • 33%
Hold Extended • 33%
New Restrictions • 34%
Tecentriq Hybreza gains the most market share • 25%
Keytruda gains the most market share • 25%
Opdivo gains the most market share • 25%
Other treatment gains the most market share • 25%
Merck • 25%
Bristol-Myers Squibb • 25%
Roche • 25%
Other • 25%
iTeos Therapeutics • 25%
GSK • 25%
Another company • 25%
No approval by end of 2025 • 25%
0-2 companies • 25%
3-5 companies • 25%
6-8 companies • 25%
More than 8 companies • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%